

# Ethical Considerations in Addressing Transmitted Drug Resistance

Arina Sablinskaja\*

Department of Microbiology, University of Tartu, Tartu, Estonia

## DESCRIPTION

The emergence and spread of Transmitted Drug Resistance (TDR) pose complex ethical challenges at the intersection of medicine, public health, and global governance. As drug-resistant pathogens threaten the effectiveness of antimicrobial therapy and exacerbate health disparities, ethical principles must guide efforts to address TDR while promoting equity, stewardship, and global health security [1].

### Ethical foundations of TDR management

Some of ethical foundations in TDR management are like follows:

**Principle of beneficence:** The principle of beneficence obligates healthcare providers, researchers, and policymakers to act in the best interests of patients and populations, striving to maximize benefits and minimize harm [2].

**Principle of justice:** Justice requires equitable distribution of resources, opportunities, and benefits, with a focus on addressing health disparities and promoting social justice. In the context of TDR, justice necessitates addressing inequities in access to healthcare, diagnostics, and antimicrobial agents, particularly in marginalized and underserved communities disproportionately affected by drug-resistant infections [3-5].

**Principle of autonomy:** Respect for patient autonomy is fundamental to ethical healthcare practice, ensuring that individuals have the right to make informed decisions about their health and treatment options [6]. In the context of TDR, autonomy involves providing patients with accurate information about the risks and benefits of antimicrobial therapy, facilitating shared decision-making, and respecting patients' preferences and values in the management of drug-resistant infections [7].

### Challenges and ethical dilemmas

Disparities in access to effective treatment for drug-resistant infections raise ethical concerns about equity, justice, and the right to health.

**Antimicrobial stewardship:** Balancing the imperative to preserve the effectiveness of antimicrobial agents through stewardship initiatives with the need to ensure access to treatment for patients with drug-resistant infections presents ethical dilemmas. Antimicrobial stewardship programs must prioritize judicious use of antibiotics while ensuring that patients receive appropriate and timely treatment, particularly in cases of severe or life-threatening infections [8-10].

**Global health security:** TDR has implications for global health security, as drug-resistant pathogens transcend national borders and pose threats to population health and economic stability [11]. Ethical considerations in global health security include equitable access to vaccines, diagnostics, and treatments for drug-resistant infections, international collaboration on surveillance and response efforts, and addressing the root causes of TDR, such as antimicrobial overuse and misuse [12].

### Strategies for ethical TDR management

Ensuring equitable access to diagnostics, antimicrobial agents, and healthcare services is essential for addressing TDR and reducing health disparities. Efforts to improve access should prioritize vulnerable populations, marginalized communities, and underserved regions through targeted interventions, capacity-building initiatives, and resource allocation strategies [13].

**Strengthening antimicrobial stewardship:** Antimicrobial stewardship programs should integrate ethical principles, including beneficence, justice, and autonomy, into their policies and practices. Emphasizing patient-centered care, evidence-based decision-making, and interdisciplinary collaboration can help optimize antimicrobial use while minimizing the emergence and spread of drug-resistant infections [14].

**Enhancing surveillance and research:** Ethical surveillance and research are critical for monitoring trends in TDR, identifying emerging resistance patterns, and informing evidence-based interventions. Surveillance systems should prioritize transparency, data sharing, and community engagement to

**Correspondence to:** Arina Sablinskaja, Department of Microbiology, University of Tartu, Tartu, Estonia, E-mail: arina.s@ut.ee

**Received:** 01-Apr-2024, Manuscript No. Ldame-24-30798; **Editor assigned:** 04-Apr-2024, PreQC No. Ldame-24-30798 (PQ); **Reviewed:** 18-Apr-2024, QC No. Ldame-24-30798; **Revised:** 25-Apr-2024, Manuscript No. Ldame-24-30798 (R); **Published:** 02-May-2024, DOI: 10.35248/2385-5495.24.10.099

**Citation:** Sablinskaja A (2024) Ethical Considerations in Addressing Transmitted Drug Resistance. *Adv Med Ethics*. 10:099.

**Copyright:** © 2024 Sablinskaja A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

promote trust, accountability, and collaboration in the global response to TDR [15].

## CONCLUSION

Transmitted Drug Resistance (TDR) presents complex ethical challenges that require interdisciplinary collaboration, ethical leadership, and a commitment to social justice and equity. By integrating ethical principles into TDR management strategies, healthcare providers, researchers, and policymakers can promote access to effective treatment, preserve the efficacy of antimicrobial agents, and protect individual and population health. Through collective action and ethical stewardship, we can address TDR while advancing the principles of beneficence, justice, and autonomy in healthcare practice, research, and policy.

## REFERENCES

1. Little SJ, Frost SD, Wong JK, Smith DM, Pond SL, Ignacio CC, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. *J Virol*. 2008;82(11):5510-5518.
2. Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips A, et al. Persistence of HIV-1 transmitted drug resistance mutations. *J Infect Dis*. 2013;208(9):1459-1463.
3. Supervie V, Garcia-Lerma JG, Heneine W, Blower S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. *Proc Natl Acad Sci*. 2010;107(27):12381-12386.
4. Smith MJ, Silva DS. Ethics for pandemics beyond influenza: Ebola, drug-resistant tuberculosis, and anticipating future ethical challenges in pandemic preparedness and response. *Monash Bioeth Rev*. 2015;33:130-147.
5. Price MA, Wallis CL, Lakhi S, Karita E, Kamali A, Anzala O, et al. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. *AIDS Res Hum Retroviruses*. 2011;27(1):5-12.
6. Wiltshire C, Bachmann N, Ssemwanga D, Scherrer AU, Nanyonjo M, Kapaata A, et al. HIV-1 drug resistance among Ugandan adults attending an urban out-patient clinic. *J Acquir Immune Defic Syndr*. 2018;78(5):566-573.
7. Zhang F, Liu L, Sun M, Sun J, Lu H. An analysis of drug resistance among people living with HIV/AIDS in Shanghai, China. *PLoS One*. 2017;12(2):e0165110.
8. Onywera H, Maman D, Inzaule S, Auma E, Were K, Fredrick H, et al. Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naive persons in rural western Kenya. *PLoS one*. 2017;12(2):e0171124.
9. Gandhi NR, Weissman D, Moodley P, Ramathal M, Elson I, Kreiswirth BN, et al. Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa. *J Infect Dis*. 2013;207(1):9-17.
10. Mamhidir AG, Lindberg M, Larsson R, Fläckman B, Engström M. Deficient knowledge of multidrug-resistant bacteria and preventive hygiene measures among primary healthcare personnel. *Journal of advanced nursing*. 2011;67(4):756-762.
11. Oliveira O, Ribeiro AI, Krainski ET, Rito T, Duarte R, Correia-Neves M. Using Bayesian spatial models to map and to identify geographical hotspots of multidrug-resistant tuberculosis in Portugal between 2000 and 2016. *Sci Rep*. 2020;10(1):16646.
12. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, et al. Multidrug-resistant *Plasmodium vivax* associated with severe and fatal malaria: a prospective study in Papua, Indonesia. *PLoS Med*. 2008;5(6):e128.
13. Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I, et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. *Nat Genet*. 2014;46(3):279-286.
14. Pearson ML, Jereb JA, Frieden TR, Crawford JT, Davis BJ, Dooley SW, et al. Nosocomial transmission of multidrug-resistant *Mycobacterium tuberculosis*: a risk to patients and health care workers. *Ann Intern Med*. 1992;117(3):191-196.
15. Artzy-Randrup Y, Alonso D, Pascual M. Transmission intensity and drug resistance in malaria population dynamics: implications for climate change. *PLoS one*. 2010;5(10):e13588.